Resverlogix presented their poster at EAS this morning according to the schedule. The poster was titled "Apabetalone (RVX-208) May Lower CVD Events in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity." The team presented a very similarly titled poster at the ACC meeting last month. Resverlogix did not have a news release specifically for announcing the ACC poster, but instead piggy backed the remaining Q1 2017 schedule of events/poster titles at the end of the 3rd DSMB news release. I haven't seen the EAS poster (they will probably put it on the website in the near future) but I am guessing that the content of the ACC and EAS posters are very similar, and that Resverlogix will not issue a news release for their EAS presentation from today. 

BearDownAZ